Literature DB >> 3070767

The present status of rabies vaccine development and clinical experience with rabies vaccine.

M Roumiantzeff1.   

Abstract

Attempts to control human rabies have a long history: animal and human vaccines provide efficient weapons for prevention. In this presentation, we would like to consider the different rabies vaccines available for human use, and particularly the modern vaccines produced in cell culture. Rabies virus is considered as an unique virus, but in fact, 5 groups of rabies fixed strains are used throughout the world to produce human rabies vaccines: Pasteur, Beijing, Flury, Fuenzalida and SAD strains. The Pasteur-derived strains, designated PV or PM, are the most widely used for the production of traditional vaccines of the Semple or Suckling Mouse Brain (SMB) types, but also for the production of modern cell culture vaccines: Human Diploid and Purified Vero Cell vaccines (HDCV and PVRV). The different rabies vaccines should be classified according to the cell system used to cultivate the virus: animal systems are still employed to produce the old traditional vaccines-Semple and SMB-which continue to be produced in several countries; Primary cell systems, particularly Hamster Kidney and Chick embryo cells, are used; Cell lines are presently the most interesting approach for vaccine production. The use of the human diploid cell system permitted the development of the HDCV, the most widely distributed cell culture rabies vaccine, and today considered as the reference vaccine. The heteroploid VERO cell line was introduced in 1982 to the production of inactivated rabies vaccine; it retained all the advantages of the Human Diploid Cell system, while offering the possibility of the large scale industrial production of PVRV. For both HDCV and PVRV, production security is guaranteed by the existence of a master cell seed and working cell bank, with a complete history of the cell, a limited number of passages and permanent and total quality control of the cell substrate. The principal human rabies vaccines produced worldwide at present using cell culture are compared, in terms of their technical characteristics and their capacity economically to face worldwide vaccine needs. The greatest needs are today in tropical countries, where only a limited amount of modern cell culture vaccines are used.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3070767

Source DB:  PubMed          Journal:  Southeast Asian J Trop Med Public Health        ISSN: 0125-1562            Impact factor:   0.267


  3 in total

1.  Short-Fragment DNA Residue from Vaccine Purification Processes Promotes Immune Response to the New Inactivated EV71 Vaccine by Upregulating TLR9 mRNA.

Authors:  Jie Shao; Fan Gao; Hui-Juan Lin; Qun-Ying Mao; Pan Chen; Xing Wu; Xin Yao; Wei Kong; Zheng-Lun Liang
Journal:  PLoS One       Date:  2016-04-15       Impact factor: 3.240

2.  The present and future of rabies vaccine in animals.

Authors:  Dong-Kun Yang; Ha-Hyun Kim; Kyung-Woo Lee; Jae-Young Song
Journal:  Clin Exp Vaccine Res       Date:  2013-01-15

3.  Immunogenicity of an inactivated rabies vaccine for animals derived from the recombinant ERAGS strain.

Authors:  Dong-Kun Yang; Ha-Hyun Kim; Yu-Ri Park; Jae Young Yoo; Yeseul Park; Sungjun An; Bang-Hun Hyun
Journal:  Clin Exp Vaccine Res       Date:  2021-05-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.